Intra-Cellular Therapies, Inc.
ITCI
Rang in Aktien
#1685
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Aktienkurs
$131.87
Zuletzt synchronisiert: 2025-04-02
Marktkapitalisierung
$12.68B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Intra-Cellular Therapies, Inc. (ITCI)
Kategorie
Healthcare
P/S-Verhältnis für Intra-Cellular Therapies, Inc. (ITCI)
P/S-Verhältnis zum October 2026 TTM: 20.63
Laut den neuesten Finanzberichten und dem Aktienkurs von Intra-Cellular Therapies, Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 20.63. Am Ende des Jahres 2023 lag das P/S-Verhältnis bei 14.79.
P/S-Verlauf für Intra-Cellular Therapies, Inc. von 2013 bis 2026
P/S-Verhältnis zum Jahresende
| Jahr | P/S-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 20.63 | 63.10% |
| 2024 | 12.65 | -14.45% |
| 2023 | 14.79 | -25.98% |
| 2022 | 19.98 | -61.62% |
| 2021 | 52.05 | -47.59% |
| 2020 | 99.31 | -99.68% |
| 2019 | 31.24K | 0.00% |
| 2018 | 0.00 | -100.00% |
| 2017 | 2.72K | 37.86% |
| 2016 | 1.97K | -90.69% |
| 2015 | 21.20K | 2,320.46% |
| 2014 | 875.93 | 827.98% |
| 2013 | 94.39 | 0.00% |
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/S-Verhältnis | P/S-Verhältnis-Differenz | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | -65.79% |
IN
|
